Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities
The RAF‑MEK‑ERK‑RSK signaling cascade is activated in prostate cancer and its activity increases with disease progression, yet targeted inhibitors have not yet translated into clinical benefit because of a lack of predictive biomarkers and unique pathway activation landscapes.
Advanced prostate cancer remains a major healthcare problem and cause of death… Clinically actionable molecular subtypes are lacking… Evidence suggests pathway activation enhances key proliferative signalling programmes and promotes cell survival… Inhibitors of the RAF-MEK-ERK-RSK pathway have demonstrated clinical utility in other cancers but this has not been realised in prostate cancer… Future studies need to identify robust predictive biomarkers…
Targeted inhibition of the RAF‑MEK‑ERK‑RSK cascade could improve outcomes in advanced prostate cancer but requires validated biomarkers to select responsive patients.
Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Kapcsolódó jelek
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience